These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 9313880

  • 1. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant.
    Frakes LA, Brehm TL, Kosty MP, Miller WE, McMillan RL, Mason J, Meisenberg BR.
    Bone Marrow Transplant; 1997 Sep; 20(6):473-8. PubMed ID: 9313880
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H, Hesketh P, Cohn J, Moriconi W, Ryan T, Friedman C, Fitts D.
    Cancer J Sci Am; 1996 Sep; 2(2):85-90. PubMed ID: 9166505
    [Abstract] [Full Text] [Related]

  • 3. Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation.
    Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin R.
    Bone Marrow Transplant; 2000 Jun; 25(12):1279-83. PubMed ID: 10871733
    [Abstract] [Full Text] [Related]

  • 4. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.
    Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin R.
    Bone Marrow Transplant; 1999 Feb; 23(3):265-9. PubMed ID: 10084258
    [Abstract] [Full Text] [Related]

  • 5. A randomized trial of once vs twice daily administration of intravenous granisetron with dexamethosone in patients receiving high-dose cyclophosphamide, thiotepa and carboplatin.
    Birch R, Weaver CH, Carson K, Buckner CD.
    Bone Marrow Transplant; 1998 Oct; 22(7):685-8. PubMed ID: 9818697
    [Abstract] [Full Text] [Related]

  • 6. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J, Trnený M, Procházka B, Klener P.
    Neoplasma; 2000 Oct; 47(5):319-22. PubMed ID: 11130251
    [Abstract] [Full Text] [Related]

  • 7. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS, Eisenberg PD, Fitts D, Friedman C, Wilson-Lynch K, Yocom K.
    Cancer; 1996 Jul 01; 78(1):144-51. PubMed ID: 8646710
    [Abstract] [Full Text] [Related]

  • 8. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP, Fisher SG, Kiley K, Fletcher-Gonzalez D, Porter N, Stiff P.
    Biol Blood Marrow Transplant; 2001 Jul 01; 7(11):596-603. PubMed ID: 11760147
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ, Tzeng WF, Wang WS, Yen CC, Fan FS, Liu JH, Chen PM.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct 01; 63(10):729-36. PubMed ID: 11076429
    [Abstract] [Full Text] [Related]

  • 10. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T, Sriswasdi C, Mongkonsritragoon W, Leelasiri A, Prayoonwiwat W.
    J Med Assoc Thai; 2002 Nov 01; 85(11):1156-63. PubMed ID: 12546311
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
    Dix S, Cord M, Howard S, Coon J, Belt R, Geller R.
    Bone Marrow Transplant; 1999 Sep 01; 24(5):561-6. PubMed ID: 10482943
    [Abstract] [Full Text] [Related]

  • 12. Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    Gynecol Oncol; 1998 Oct 01; 71(1):113-5. PubMed ID: 9784330
    [Abstract] [Full Text] [Related]

  • 13. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
    Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.
    Bone Marrow Transplant; 2001 Feb 01; 27(3):269-78. PubMed ID: 11277174
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
    Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O.
    J Oncol Pharm Pract; 2010 Mar 01; 16(1):45-51. PubMed ID: 19525301
    [Abstract] [Full Text] [Related]

  • 15. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ, Gandara DR, Hesketh AM, Edelman M, Webber LM, McManus M, Hainsworth JD.
    Cancer J Sci Am; 1997 Mar 01; 3(3):180-3. PubMed ID: 9161784
    [Abstract] [Full Text] [Related]

  • 16. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C.
    Cancer J Sci Am; 1998 Mar 01; 4(1):52-8. PubMed ID: 9467047
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
    Jones E, Koyama T, Ho RH, Kuttesch J, Shankar S, Whitlock JA, Cartwright J, Frangoul H.
    Pediatr Blood Cancer; 2007 Mar 01; 48(3):330-2. PubMed ID: 16304666
    [Abstract] [Full Text] [Related]

  • 18. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
    Demirer T, Ilhan O, Mandel NM, Arat M, Günel N, Celebi H, Ustün C, Akan H, Demirer S, Aydintuğ S, Uysal A, Koç H.
    Bone Marrow Transplant; 2000 Apr 01; 25(7):697-703. PubMed ID: 10745253
    [Abstract] [Full Text] [Related]

  • 19. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.
    Walsh T, Morris AK, Holle LM, Callander N, Bradshaw P, Valley AW, Clark G, Freytes CO.
    Bone Marrow Transplant; 2004 Dec 01; 34(11):963-8. PubMed ID: 15489869
    [Abstract] [Full Text] [Related]

  • 20. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy.
    Hesketh PJ, Crews JR, Cohen R, Blackburn LM, Friedman CJ.
    Cancer J; 2000 Dec 01; 6(3):157-61. PubMed ID: 10882331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.